Will Photofrin PDT Reduce Risk of Esophageal Cancer?
Will Photofrin PDT Reduce Risk of Esophageal Cancer? Tuesday September 13, 2005 Photofrin PDT reduces esophageal cancer occurrence in patients with Barrett’s High Grade Dysplasia – Results of a 5-year follow-up study Press Release MONT SAINT-HILAIRE, QC, Sept. 13 /PRNewswire-FirstCall/ Coinciding with the World Congress of Gastroenterology 2005 being held in Montreal, Canada, Axcan Pharma Inc. (“Axcan” or the “Company”) disclosed new data demonstrating that Photofrin photodynamic therapy (“PDT”) used in conjunction with omeprazole, a standard acid suppression therapy, reduced occurrence of esophageal cancer. This new clinical information is based on the analysis of the 5-year follow-up observation of patients with High Grade Dysplasia (“HGD”) associated with Barrett’s esophagus (“BE”) who were randomized in the original pivotal 2-year Phase III study conducted by Axcan which led to regulatory approval in 2003. Since HGD and the eventual possibility of developing cancer in BE are inextr
